The patients were actually followed for 281 days in the control group and 279 days in the intervention group, (p=0.871).
By 52 weeks, there were 13 deaths in the control group and 11 deaths in the intervention group, (p=0.830).
The rate of re-hospitalisation or deaths at 52 weeks was 61.2% (control) and 47.5% (intervention), respectively, (p=0.01).
The distribution of times to first readmission or death was shifted toward longer time intervals in the intervention group than in the control group, (p=0.026).
The proportions of patients remaining alive and with no hospital readmission were:
in the intervention group, 0.869 (+/- 0.033) at 30 days, 0.750 (+/- 0.043) at 60 days, 0.071 (+/- 0.045) at 90 days, 0.600 (+/- 0.047) at 180 days and 0.445 (+/- 0.050) at 365 days; and
in the control group, 0.737 (+/- 0.041) at 30 days, 0.621 (+/- 0.046) at 60 days, 0.558 (+/- 0.047) at 90 days, 0.444 (+/- 0.047) at 180 days and 0.321 (+/- 0.046) at 365 days.
These differences were statistically significant at any time point.
Similarly, the estimated median event-free survival of patients was 131 days in the intervention group and 241 days in the control groups.
There were no statistically significant group differences by time interactions.
The crude IDR was 1.48 (95% CI: 1.05 - 2.09; p=0.027).
The multivariate model-adjusted IDR was 1.65 (95% CI: 1.13 - 2.40; p=0.001).
There was a non significant trend towards fewer patients re-hospitalised in the intervention group.
The total number of re-hospitalisations was 104 in the intervention group and 162 in the control group, (p<0.047).
The number of re-hospitalisation per patient per year was 1.18 in the intervention group and 1.79 in the control group, (p<0.001).
The total hospital days were 588 in the intervention group versus 970 in the control group.
The mean hospital days per patient and per re-hospitalised patient were not statistically significant.
The intervention effect declined slightly as the time post-intervention increased. Differences between the groups were greatest during the first 3 months.
At 12 weeks, the overall quality of life score was better in the intervention group (3.2 +/- 1.5) than in the control group (2.7 +/- 1.5), (p<0.05).
Significantly better results in the intervention group were observed for the physical dimension of quality of life at 2 and 12 weeks.
Satisfaction with care was significantly higher in the intervention group at both 2 weeks (83 +/- 10.3 versus 74.6 +/- 10.4; p<0.001) and 6 weeks (83.1 +/- 9.6 versus 77.8 +/- 11.2; p<0.001).
No statistically significant differences were observed in terms of functional status scores at any time point.